Antimicrobial resistance – a challenge for public health

• Authors: Waleria Hryniewicz

Abstracts

EN

Penicillin, the first antibiotic introduced into clinical practice opened a new era in medicine. The ‘golden age’ of antibiotic discoveries in the 1950s, 60s and 70s significantly helped our fight against bacterial infections. In parallel with the introduction of new drugs, resistance strains were identified. This was, however, neglected because of the belief that pharmaceutical companies would continuously supply us with new products. In contrary, a pipeline of new antibiotics slowly dried out and in the 1980s we realized that the proportion of resistant bacteria was increasing faster than the supply of new antibiotics. New mechanisms of resistance emerged and multidrug and pandrug resistant bacterial strains started to spread globally. Antimicrobial resistance is recognized now as one of the greatest threats to public health worldwide. The WHO and EU as well as national agencies are calling for actions which should be immediately undertaken if we do not want to lose the battle.

Keywords

EN

antimicrobial resistance; call for actions to contain antibiotic resistance; rational antibiotic use

PL

działania ograniczające oporność na antybiotyki; oporność na antybiotyki; racjonalne stosowanie antybiotyków

• Publisher: Uniwersytet Jagielloński
• Journal: Zdrowie Publiczne i Zarządzanie
• Year: 2019
• Volume: 17
• Issue: 1
• Pages: 32-39

Dates

published

2019

Contributors

author

Waleria Hryniewicz

• Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw

• https://orcid.org/0000000236519790

References

• Finch R., Greenwood D., Norrby S.R., Whitley R.JU., Antibiotic Chemotherapy, Saunders Elsevier, Edinburgh‒ London‒New York‒Sydney‒Toronto 2010.
• Grayson M.L (ed.), Kucers’ the Use of Antibiotics, ed. 7, CRC Press, Boca Raton 2018.
• Ma S., Xu Y., Nodwell J.R., The expression of antibiotic resistance genes in antibiotic-producing bacteria, “Mol. Microbiol.” 2014; 93: 391‒401.
• Juhas M., Horizontal gene transfer in human pathogens, “Crit. Rev. Microbiol.” 2015; 41: 101‒108.
• Berglund B., Environmental dissemination of antibiotic resis- tance genes and correlation to anthropogenic contamination with antibiotics, “Infect. Ecol. Epidemiol.” 2015; 5.
• Jevons M.P., “Celbenin” ‒ resistant Staphylococci, “Br. Med. J.” 1961; 1: 124–125.
• Moellering R.C., MRSA: The first half century, “J. Antimicrob. Chemother.” 2012; 67: 4‒11.
• Rolo J., Worning P., Nielsen J.B. et al., Evolutionary origin of the staphylococcal cassette chromosome mec (SCCmec), “Antimicrob. Agents Chemother.” 2017; 61 pii: e02302-16.
• Gniadkowski M., Evolution of extended¬spectrum beta¬lactamases by mutation, “Clin. Microbiol. Infect.” 2008; Suppl 1: 11‒32.
• Livermore D.M., Beta¬lactamases in laboratory and clinical resistance, “Clin. Microbiol. Rev.” 1995; 8: 557‒584.
• van Duin D., Doi Y., The global epidemiology of carbapenemase-producing Enterobacteriaceae, “Virulence” 2017; 8: 460‒469.
• Kwiatkowski Z., Markiewicz Z., Bakterie ‒ antybiotyki ‒oporność, Wydawnictwo Naukowe PWN, Warszawa 2019.
• Cassini A., Diaz Hogberg L., Plachouras D. et al., Attrib¬ utable deaths and disability-adjusted life¬years caused by infections with antibiotic¬resistant bacteria in the EU and the European Economic Area in 2015: A population¬level modeling analysis, “Lancet Infect. Dis.” 2019; 19: 56‒66.
• New estimate of annual deaths caused by treatment resis¬ tant infections highlights gaps in research, stewardship, surveillance, Idsiciety.org/news (accessed: 22.06.2019).
• Rozporządzenie Ministra Zdrowia z dnia 23 grudnia 2011 roku w sprawie listy czynników alarmowych, rejestrów zakażeń szpitalnych i czynników alarmowych oraz raportów o bieżącej sytuacji epidemiologicznej szpitala (Dziennik Ustaw z 2011 roku Nr 294 poz.1741).
• Rice L.B., Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE, “J. Infect. Dis.” 2008; 197: 1079‒1081.
• Antimicrobial resistance global report on surveillance, WHO, Geneva 2014.
• Magiorakos A.P., Srinivasan A., Carey R.B. et al., Multi¬ drug¬resistant, extensively drug-resistant and pandrug¬re¬ sistant bacteria: An international expert proposal for in- terim standard definitions for acquired resistance, “Clin. Microbiol. Infect.” 2012; 18: 268‒281.
• Tacconelli E., Carrara E., Savoldi A., WHO 2017 discovery, research, and development of new antibiotics: The WHO priority list of antibiotic¬resistant bacteria and tuberculo¬ sis, “Lancet Infect. Dis.” 2018; 18: 318‒327.
• Review on Antimicrobial Resistance. Antimicrobial Resis- tance: Tackling a Crisis for the Health and Wealth of Na- tions, Wellcome Trust and HM Government, London 2014.
• Xu L., Sun X., Ma X., Systemic review and meta-analysis of mortality of patients infected with carbapenem¬resistant Klebsiella pneumonia, “Ann. Clin. Microbiol. Antim crob.” 2017; 16: 18.
• Martirosian G., Hryniewicz W., Ozorowski T. et al., Zaka¬ żenia Clostridioides (Clostridium) difficile: epidemiologia, diagnostyka, terapia, profilaktyk, Narodowy Instytut Leków, Warszawa 2018.
• Olczak-Pieńkowska A., Skoczyńska A., Hryniewicz W., Monthly trends in antimicrobial consumption and influenza incidence at the community level in 2014 in Poland, “Pol. Arch. Intern. Med.” 2018; 128: 731‒738.
• Izdebski R., Baraniak A., Bojarska K. et al., Mobile MCR¬1-associated resistance to colistin in Poland, “J. Antimicrob. Chemother.” 2016; 71: 2331‒2333.
• D’Atri F., Arthur J., Blix H.S., Targets for the reduction of antibiotic use in humans in the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) partner countries, “Euro Surveill.” 2019; 24.
• Tyrstrup M., Melander E., Hedin K. et al., Children with respiratory tract infections in Swedish primary care; prevalence of antibiotic resistance in common respiratory tract pathogens and relation to antibiotic consumption, “BMC Infect. Dis.” 2017; 17: 603.

Identifiers

DOI

10.4467/20842627OZ.19.005.11301

Biblioteka Nauki

2188040